COMPASS Pathways PLC (CMPS)

Form 8-K - Current report

Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile

New 6-month data supports COMP360’s potential to establish a new standard of care in TRD Data from positive COMP006 Phase 3 trial demonstrates...

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology...

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year Canada...

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Compass Pathways Elects Kathleen Tregoning to Board of Directors

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...

Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]